Kissei Pharmaceuticals   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Matsumoto Japan (1946)

Organization Overview

First Clinical Trial
2006
NCT00461617
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Clinical Development Department, Kissei pharmaceutical Co., Ltd. | Clinical Development Department, Kissei Pharmaceutical Co., Ltd. | Kissei Pharmaceutical Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Calculi (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Constipation (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dry Eye Syndromes (Phase 3)

Endometriosis (Phase 2)

Hyperphosphatemia (Phase 3)

Hyperplasia (Phase 2)

Hyperuricemia (Phase 2)

Keratoconjunctivitis Sicca (Phase 3)

Kidney Diseases (Phase 2)

Mesothelioma (Phase 2)

Parkinson Disease (Phase 2)

Prostatic Hyperplasia (Phase 2)

Pruritus (Phase 2)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Renal Insufficiency, Chronic (Phase 2)

Sjogren's Syndrome (Phase 3)

Spinocerebellar Ataxias (Phase 3)

Spinocerebellar Degenerations (Phase 3)

Syndrome (Phase 3)

Ulcer (Phase 3)

Urinary Bladder, Overactive (Phase 3)

Urinary Calculi (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 54
  • # of Trial APIs: 23